SCHEMBL16201414

SCHEMBL16201414

CCCN(C)Cc1c[nH]nc1-c1ccc(OC)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 3/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TSHR P16473 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
ALDH1A1 P00352 2/20 0.35
TGFBR1 P36897 1/20 0.35
GAA P10253 2/20 0.35
MAPT P10636 1/20 0.35
PRMT3 O60678 1/20 0.35
CARM1 Q86X55 1/20 0.35
PRMT6 Q96LA8 1/20 0.35
PRMT8 Q9NR22 1/20 0.35
CCNB2 O95067 1/20 0.34
CDK1 P06493 1/20 0.34
CCNB1 P14635 1/20 0.34
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
CDK5 Q00535 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201245 0.88 PRMT1 (0.47) PRMT1MEN1KMT2ATSHRNPC1
SCHEMBL16201419 0.88 MEN1 (0.41) MEN1KMT2ARAB9AALDH1A1GAA
SCHEMBL16201421 0.86 MEN1 (0.36) PRMT1MEN1KMT2AALDH1A1GAA
SCHEMBL16201361 0.86 PRMT6 (0.45) PRMT1TSHRPRMT6GSK3B
SCHEMBL16201436 0.86 ALDH1A1 (0.42) MEN1KMT2ATSHRRAB9AALDH1A1
SCHEMBL16204220 0.86 PRMT1 (0.58) PRMT1MEN1KMT2ATSHRCARM1
SCHEMBL16201332 0.86 PRMT1 (0.51) PRMT1MAPTPRMT3CARM1PRMT6
SCHEMBL16201347 0.85 CRHR1 (0.38) PRMT1MEN1KMT2ATSHRNPC1
SCHEMBL16201317 0.85 KDM4E (0.34) ALDH1A1GAAMAPTKDM4ELMNA
SCHEMBL16201345 0.85 PRMT3 (0.40) PRMT1MEN1KMT2ARAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9776972-B2 Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof EPIZYME INC. (US) 2017-10-03 US disclosed
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-05-19 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 PRMT1 1/4885MEN1 1218/4885KMT2A 65/4885
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 PRMT1 1/4885MEN1 1839/4885KMT2A 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.